BNF 85 (British National Formulary) March 2023

The British National Formulary (BNF) is the first choice for concise medicines information, trusted by health professionals worldwide. The new edition (BNF 85) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines. Extensive content updates include new monographs for various medicines, as well as MHRA advice on risk of thrombosis, denosumab, dexmedetomidine, metformin hydrochloride, methylphenidate hydrochloride long-acting preparations, nebulised asthma rescue therapy in children, rucaparib, topiramate, COVID-19 vaccines, depression, diphtheria vaccine, epilepsy, gout, post-exposure prophylaxis of herpesvirus infections, hydrocortisone, management of hypertension in patients with type 1 diabetes, multiple sclerosis, obstetrics, tacrolimus, type 1 diabetes, and type 2 diabetes. Order your copy today and get up-to-date information on prescribing, dispensing, and administering medicines, authoritative, independent guidance on best practice, and everything you need at your fingertips.

Format: Paperback / softback
Length: 1864 pages
Publication date: 22 March 2023
Publisher: Pharmaceutical Press

The British National Formulary (BNF) stands as the premier resource for concise and reliable medicines information, trusted by healthcare professionals worldwide. Its eighth edition (BNF 85), released recently, offers invaluable guidance on prescribing, dispensing, and administering medications, along with comprehensive legal and professional guidelines. This edition boasts extensive content updates, encompassing new monographs for various medications. These include Aklief® (trifarotene) for acne vulgaris, Drovelis® (drospirenone with estetrol) for hormonal contraception, Ducressa® (dexamethasone with levofloxacin) for prophylaxis or treatment of postoperative inflammation, or prevention of infection following cataract surgery, Kerendia® (finerenone) for chronic kidney disease associated with type 2 diabetes, Magnesium citrate for treatment and prevention of magnesium deficiency, Netildex® (dexamethasone with netilmicin) for local treatment of eye inflammation and bacterial infection, Nettacin® (netilmicin) for local treatment of eye infection, Sibnayal® (potassium citrate with potassium bicarbonate) for distal renal tubular acidosis, Tenkasi® (oritavancin) for acute bacterial skin and skin structure infections, and Vydura® (rimegepant) for treatment or prophylaxis of migraine. Additionally, the MHRA has provided valuable advice on several medications, including Anagrelide, Denosumab (Prolia®), Dexmedetomidine, Metformin hydrochloride, and Methylphenidat. These advisories highlight important considerations for healthcare professionals when prescribing and managing these medications. By incorporating the latest information from the BNF 85 edition, healthcare practitioners can ensure that they are providing the most effective and safe treatment options for their patients.

ISBN-13: 9780857114587
Edition number: 85 ed